RxDoctor Payments Data

Sanjay Asrani, MD

Glaucoma Specialist · Cary, NCNPI 1003960121

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (46.5%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. Aerie Pharmaceuticals, Inc. accounts for 75.6% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $7,249 and has fallen 97.8% since, to $157 in 2023.

$9,006in general payments, 2019–2025

Across 15 payments — averaging $600.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aerie Pharmaceuticals, Inc.$7K
  • Heidelberg Engineering, Inc.$900
  • Eyepoint US, Inc.$873
  • Alcon$267
  • Glaukos Corporation$157

What the payments were for

  • Consulting fees$3,21536%
  • Speaking & faculty fees$90010%
  • Travel & lodging$4,18847%
  • Food & beverage$7038%

General payments by program year

19
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in North Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$160,459
Medicare patients
352
Services billed
1,814

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate184$5,549
RhopressaNetarsudil Mesylate11$5,358
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat186$3,910
Latanoprost214$2,936
Dorzolamide Hcl69$1,505
Brimonidine Tartrate118$1,120
Timolol Maleate79$848
Ketorolac Tromethamine63$806
Atropine Sulfate16$569
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim74$531

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rhopressa$6,808$5,35811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in North Carolinaon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Cary

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →